The Journal of Headache and Pain

, Volume 8, Issue 5, pp 273–276

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment

Open Access
Comment

Abstract

The clinical efficacy in migraine was compared for oral and subcutaneous sumatriptan and naratriptan. Doses of the two administration forms were chosen as resulting in comparable blood concentrations. Subcutaneous administrations of the drugs were superior for efficacy than the oral forms. This most likely due to a quicker rise in blood concentrations after subcutaneous injections.. In designing new therapies for migraine one should aim at a quick absorption of the drug, which will probably result in an increased efficacy.

Keywords

Migraine Sumatriptan Naratriptan Oral administration Subcutaneous administration 

References

  1. 1.
    Thomsen LL, Dixon R, Lassen LH et al (1996) 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 16:270–275, 10.1046/j.1468-2982.1996.1604270.x, 1:STN:280:DyaK28zosVWnsQ%3D%3D, 8792040CrossRefPubMedGoogle Scholar
  2. 2.
    Sternieri E, Pinetti D, Coccia CP et al (2005) Pharmacokinetics of sumatriptan in non-responders and in adverse drug reaction reporting migraine patients. J Headache Pain 6:319–321, 10.1007/s10194-005-0220-z, 1:CAS:528:DC%2BD28XmvFGmurs%3D, 16362699PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Visser WH, Burggraaf and adverse J, Muller LM et al (1996) Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 60:452–460, 10.1016/S0009-9236(96)90202-7, 1:CAS:528:DyaK28XmvFWku7s%3D, 8873693CrossRefPubMedGoogle Scholar
  4. 4.
    Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Ed. Philadelphia: Lippincott Williams & Wilkins 469–503Google Scholar
  5. 5.
    Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259–1287CrossRefPubMedGoogle Scholar
  6. 6.
    Tfelt-Hansen P (1993) Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia 13:238–244, 10.1046/j.1468-2982.1993.1304238.x, 1:STN:280:DyaK3szos1Ogtw%3D%3D, 8397070CrossRefPubMedGoogle Scholar
  7. 7.
    Humphrey PP (2007) The discovery of a new drug class for the acute treatment of migraine. Headache 47(Suppl 1):S10–S19, 10.1111/j.1526-4610.2007.00672.x, 17425704CrossRefPubMedGoogle Scholar
  8. 8.
    Lacey LF, Hussey EK, Fowler PA (1995) Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47:543–548, 10.1007/BF00193709, 1:CAS:528:DyaK2MXmtVWntL8%3D, 7768259CrossRefPubMedGoogle Scholar
  9. 9.
    Dahlöf C, Hogenhuis L, Olesen J et al (1998) Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 5:469–477, 10.1046/j.1468-1331.1998.550469.x, 10210876CrossRefPubMedGoogle Scholar
  10. 10.
    Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/!D agonists) in acute migraine: a meta-analysis of 53 trials. Lancet 358:1668–1675, 10.1016/S0140-6736(01)06711-3, 1:CAS:528:DC%2BD3MXos1ajsro%3D, 11728541CrossRefPubMedGoogle Scholar
  11. 11.
    International Headache Society Clinical Trial Subcommittee (2000) Guidelines for controlled trials of drugs in migraine. Second edition. Cephalalgia 20:765–786, 10.1046/j.1468-2982.2000.00117.xCrossRefGoogle Scholar
  12. 12.
    Oral Sumatriptan Dose Defining Study Group (1991) Sumatriptan — an oral dose defining study. Eur Neurol 31:300–305, 10.1159/000116632CrossRefGoogle Scholar
  13. 13.
    Mathew NT, Dexter J, Couch J et al (1992) Dose ranging efficacy of safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Study Group. Arch Neurol 49:1271–1276, 1:STN:280:DyaK3s%2FotVCktw%3D%3D, 1333181CrossRefPubMedGoogle Scholar
  14. 14.
    Visser WH, Ferrari MD, Bayliss EM et al (1992) Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia 12:308–313, 10.1046/j.1468-2982.1992.1205308.x, 1:STN:280:DyaK3s%2Fks1GqsA%3D%3D, 1330318CrossRefPubMedGoogle Scholar
  15. 15.
    Havanka H, Dahlöf C, Pop H et al (2000) Efficacy of naratriptan in the acute treatment of migraine: a dose-ranging study. Naratriptan S2BW2004 Study Group. Clin Ther 22:970–980, 10.1016/S0149-2918(00)80068-5, 1:CAS:528:DC%2BD3cXmsFSqtLw%3D, 10972633CrossRefPubMedGoogle Scholar
  16. 16.
    Mathew NT, Asgharenjad M, Peykamian M, Laurenza A (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 49:485–490CrossRefGoogle Scholar
  17. 17.
    Klassen A, Elkind A, Asgharnejad M et al (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. The Naratriptan S2WA3001 Study Group. Headache 37:640–645, 10.1046/j.1526-4610.1997.3710640.x, 1:STN:280:DyaK1c7gt1SksA%3D%3D, 9439085CrossRefPubMedGoogle Scholar
  18. 18.
    Tfelt-Hansen P. Maximum effect of triptans in migraine? A comment. Cephalalgia, in pressGoogle Scholar
  19. 19.
    Volans GN (1974) Absorption of effervescent aspirin during migraine. BMJ 4:265–269, 10.1136/bmj.4.5939.265, 1:STN:280:DyaE2M%2Fjs1yjsQ%3D%3D, 4425854PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Tfelt-Hansen P, Young WB, Silberstein SD (2006) Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Eds. Philadelphia: Lippincott Williams & Wilkins 505–513Google Scholar
  21. 21.
    Jhee SS, Shiovitz T, Crawford AW, Cutler NR (2001) Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 40:189–205CrossRefPubMedGoogle Scholar
  22. 22.
    Sumatriptan Cluster Headache Study Group (1991) Treatment for acute cluster headache with sumatriptan. N Eng J Med 325:322–326, 10.1056/NEJM199108013250505CrossRefGoogle Scholar
  23. 23.
    Connor HE, Feniuk W, Beattie DT et al (1997) Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 17:145–152, 10.1046/j.1468-2982.1997.1703145.x, 1:STN:280:DyaK2szhtl2gtw%3D%3D, 9170336CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  1. 1.Danish Headache Centre Department of NeurologyUniversity of Copenhagen Glostrup HospitalGlostrupDenmark

Personalised recommendations